Sanofi alum Sibold named CEO at Madrigal
Plus: Fenimore to succeed Landry as Regeneron CFO and updates from SpringWorks, SalioGen, Oxular, Solu, Flagship, Oculis
Bill Sibold succeeded Paul Friedman as CEO of Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL), which is developing therapies for non-alcoholic steatohepatitis. Sibold was most recently EVP, specialty care and president of the North America division at Sanofi (Euronext:SAN; NASDAQ:SNY), where he held roles for almost 12 years. Friedman, who became CEO in 2016, will continue as a board member; Sibold will also join Madrigal’s board.
Robert Landry will retire as EVP, finance and CFO of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) in February 2024, after a decade at the company. Landry will be succeeded by SVP, Head of Accounting and Controller Christopher Fenimore, who joined Regeneron in 2003 as VP of financial planning and analysis. The company also announced that Marc Tessier-Lavigne retired as a board member on Sept.1, a day after he stepped down as Stanford's president. ...